This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) will release its second quarter 2018 financial and operating results on Thursday, August 2, 2018 at approximately 6:00 a.m. ET. A conference call and webcast hosted by management will follow at 8:30 a.m. ET to review the Company’s results and discuss the quarter’s highlights.
Boss Resources Ltd (ASX:BOE) has hit near-surface and deeper gold intersections during drilling at three prospects within its Golden Hill property in Burkina Faso.
TGZ BOE TGZ
TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce that its most recent diamond drill program on the Golden Hill property in Burkina Faso, West Africa has returned near surface and deeper gold intersections that will enhance resources at a number of advanced prospects. In addition, the recent drilling evaluation program identified a new near-surface discovery at Peksou North, one of 9 prospects drilled at Golden Hill over the past 18 months.
TGZ BOE TGZ
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation (“Teranga” or the “Company”) (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce an updated mineral resource estimate for its Wahgnion gold development project (“Wahgnion”) in Burkina Faso, West Africa.
In my opinion, the company is heading in the right direction: Sabodala performs well and the Wahgnion gold project in Burkina Faso is entering the development stage.
KGI KGI.DB.A RGORF KGI.DB EDVMF GRY GOLD RRS GPHYF GOLD TGZ TGZ EDVVF EVR KL EDV GSC
TORONTO, May 08, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation (“Teranga” or the “Company”) (TSX:TGZ) (OTCQX:TGCDF) announces that all nominee directors listed in the Management Proxy Circular dated April 3, 2018 were elected as directors of the Company at its Annual General Meeting of Shareholders (the “Meeting”) held earlier today in Toronto, Ontario. At this Meeting, 69,914,888 shares were voted, representing 65.
TORONTO, May 07, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation (“Teranga” or the “Company”) (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce that it has satisfied all conditions precedent for its first drawdown under the secured development finance facility with Taurus Funds Management Pty Ltd. (the “Facility”). The Facility is comprised of $165 million (the “PF Tranche”) to be used towards funding the development of the Wahgnion Gold Project (“Wahgnion”) and to repay all of the Company’s current outstanding bank debt totaling $15 million drawn on its revolving credit facility with Société Générale.
Good morning, and welcome to Teranga Gold Conference Call for the First Quarter and Year Ended March 31, 2018. As a reminder, this conference call is being recorded. Your host for today is Trish Moran, Head of Investor Relations. Ms. Moran, please go ahead.
TORONTO, May 03, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) today reported its financial and operating results for the three months ended March 31, 2018.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...